# Intellinetics, Inc.: financial statements, quarterly

INLX · NYSE · CIK 1081745 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/inlx.md) · [Financials](/companies/inlx/financials.md) · [Filings](/companies/inlx/filings.md) · [Insiders](/companies/inlx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/inlx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [4,248](/filings/0001493152-24-045106.md) | [4,193 d](/filings/0001641172-25-000274.md) | [4,507](/filings/0001641172-25-009938.md) | [4,642](/filings/0001641172-25-023453.md) | [4,590](/filings/0001493152-25-021891.md) | [4,280 d](/filings/0001493152-26-013568.md) | [4,247](/filings/0001493152-26-023045.md) | [4,011](/filings/0001493152-26-037331.md) | [4,001](/filings/0001493152-25-021891.md) | [4,324 d](/filings/0001493152-26-013568.md) | [3,909](/filings/0001493152-26-023045.md) | [3,946](/filings/0001493152-26-037331.md) |
| Cost of revenue | $k | [1,643](/filings/0001493152-24-045106.md) | [1,471 d](/filings/0001641172-25-000274.md) | [1,607](/filings/0001641172-25-009938.md) | [1,639](/filings/0001641172-25-023453.md) | [1,844](/filings/0001493152-25-021891.md) | [1,508 d](/filings/0001493152-26-013568.md) | [1,420](/filings/0001493152-26-023045.md) | [1,284](/filings/0001493152-26-037331.md) | [1,434](/filings/0001493152-25-021891.md) | [1,444 d](/filings/0001493152-26-013568.md) | [1,427](/filings/0001493152-26-023045.md) | [1,327](/filings/0001493152-26-037331.md) |
| Gross profit | $k | [2,606](/filings/0001493152-24-045106.md) | [2,722 d](/filings/0001641172-25-000274.md) | [2,900](/filings/0001641172-25-009938.md) | [3,003](/filings/0001641172-25-023453.md) | [2,746](/filings/0001493152-25-021891.md) | [2,772 d](/filings/0001493152-26-013568.md) | [2,827](/filings/0001493152-26-023045.md) | [2,727](/filings/0001493152-26-037331.md) | [2,568](/filings/0001493152-25-021891.md) | [2,880 d](/filings/0001493152-26-013568.md) | [2,482](/filings/0001493152-26-023045.md) | [2,619](/filings/0001493152-26-037331.md) |
| Research and development | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [346](/filings/0001493152-24-045106.md) | [182 d](/filings/0001641172-25-000274.md) | [(34.5)](/filings/0001641172-25-009938.md) | [172](/filings/0001641172-25-023453.md) | [(298)](/filings/0001493152-25-021891.md) | [(12.9) d](/filings/0001493152-26-013568.md) | [(685)](/filings/0001493152-26-023045.md) | [(508)](/filings/0001493152-26-037331.md) | [(379)](/filings/0001493152-25-021891.md) | [(216) d](/filings/0001493152-26-013568.md) | [(1,183)](/filings/0001493152-26-023045.md) | [(1,090)](/filings/0001493152-26-037331.md) |
| Interest expense | $k | [136](/filings/0001493152-24-045106.md) | [120 d](/filings/0001641172-25-000274.md) | [140](/filings/0001641172-25-009938.md) | [97.1](/filings/0001641172-25-023453.md) | [94.6](/filings/0001493152-25-021891.md) | [40.8 d](/filings/0001493152-26-013568.md) | [43.0](/filings/0001493152-26-023045.md) | [59.1](/filings/0001493152-26-037331.md) | [(9.5)](/filings/0001493152-25-021891.md) | [(8.3) d](/filings/0001493152-26-013568.md) | [(4.7)](/filings/0001493152-26-023045.md) | [(3.9)](/filings/0001493152-26-037331.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [209](/filings/0001493152-24-045106.md) | [61.6 d](/filings/0001641172-25-000274.md) | [(175)](/filings/0001641172-25-009938.md) | [75.1](/filings/0001641172-25-023453.md) | [(393)](/filings/0001493152-25-021891.md) | [(53.7) d](/filings/0001493152-26-013568.md) | [(728)](/filings/0001493152-26-023045.md) | [(568)](/filings/0001493152-26-037331.md) | [(370)](/filings/0001493152-25-021891.md) | [(208) d](/filings/0001493152-26-013568.md) | [(1,178)](/filings/0001493152-26-023045.md) | [(1,086)](/filings/0001493152-26-037331.md) |
| Diluted EPS | $ per share | [0.05](/filings/0001493152-24-045106.md) | not reported | [(0.04)](/filings/0001641172-25-009938.md) | [0.02](/filings/0001641172-25-023453.md) | [(0.09)](/filings/0001493152-25-021891.md) | not reported | [(0.17)](/filings/0001493152-26-023045.md) | [(0.13)](/filings/0001493152-26-037331.md) | [(0.08)](/filings/0001493152-25-021891.md) | not reported | [(0.27)](/filings/0001493152-26-023045.md) | [(0.24)](/filings/0001493152-26-037331.md) |
| Basic EPS | $ per share | [0.05](/filings/0001493152-24-045106.md) | not reported | [(0.04)](/filings/0001641172-25-009938.md) | [0.02](/filings/0001641172-25-023453.md) | [(0.09)](/filings/0001493152-25-021891.md) | not reported | [(0.17)](/filings/0001493152-26-023045.md) | [(0.13)](/filings/0001493152-26-037331.md) | [(0.08)](/filings/0001493152-25-021891.md) | not reported | [(0.27)](/filings/0001493152-26-023045.md) | [(0.24)](/filings/0001493152-26-037331.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.7](/filings/0001493152-23-041026.md) | [1.2](/filings/0001641172-25-000274.md) | [1.2](/filings/0001493152-24-019215.md) | [1.7](/filings/0001493152-24-031586.md) | [2.5](/filings/0001493152-24-045106.md) | [2.5](/filings/0001641172-25-023453.md) | [2.1](/filings/0001641172-25-009938.md) | [2.1](/filings/0001641172-25-023453.md) | [3.2](/filings/0001493152-25-021891.md) | [2.5](/filings/0001493152-26-037331.md) | [2.1](/filings/0001493152-26-023045.md) | [1.7](/filings/0001493152-26-037331.md) |
| Current assets | $m | [4.9](/filings/0001493152-23-041026.md) | [5.0](/filings/0001641172-25-000274.md) | [5.0](/filings/0001493152-24-019215.md) | [5.2](/filings/0001493152-24-031586.md) | [5.5](/filings/0001493152-24-045106.md) | [5.5](/filings/0001493152-26-013568.md) | [5.1](/filings/0001641172-25-009938.md) | [4.6](/filings/0001641172-25-023453.md) | [5.5](/filings/0001493152-25-021891.md) | [5.2](/filings/0001493152-26-037331.md) | [4.7](/filings/0001493152-26-023045.md) | [3.8](/filings/0001493152-26-037331.md) |
| Total assets | $m | [19.2](/filings/0001493152-23-041026.md) | [19.0](/filings/0001641172-25-000274.md) | [18.9](/filings/0001493152-24-019215.md) | [18.9](/filings/0001493152-24-031586.md) | [19.0](/filings/0001493152-24-045106.md) | [18.6](/filings/0001493152-26-013568.md) | [18.0](/filings/0001641172-25-009938.md) | [17.2](/filings/0001641172-25-023453.md) | [18.0](/filings/0001493152-25-021891.md) | [17.3](/filings/0001493152-26-037331.md) | [16.5](/filings/0001493152-26-023045.md) | [15.6](/filings/0001493152-26-037331.md) |
| Current liabilities | $m | [4.8](/filings/0001493152-23-041026.md) | [4.4](/filings/0001641172-25-000274.md) | [4.9](/filings/0001493152-24-019215.md) | [4.7](/filings/0001493152-24-031586.md) | [5.7](/filings/0001493152-24-045106.md) | [6.6](/filings/0001493152-26-013568.md) | [6.5](/filings/0001641172-25-009938.md) | [4.7](/filings/0001641172-25-023453.md) | [5.6](/filings/0001493152-25-021891.md) | [5.1](/filings/0001493152-26-037331.md) | [5.2](/filings/0001493152-26-023045.md) | [5.1](/filings/0001493152-26-037331.md) |
| Total liabilities | $m | [9.9](/filings/0001493152-23-041026.md) | [9.3](/filings/0001641172-25-000274.md) | [8.9](/filings/0001493152-24-019215.md) | [8.5](/filings/0001493152-24-031586.md) | [8.6](/filings/0001493152-24-045106.md) | [7.9](/filings/0001493152-26-013568.md) | [7.6](/filings/0001641172-25-009938.md) | [5.6](/filings/0001641172-25-023453.md) | [6.6](/filings/0001493152-25-021891.md) | [5.9](/filings/0001493152-26-037331.md) | [6.0](/filings/0001493152-26-023045.md) | [5.8](/filings/0001493152-26-037331.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [9.4](/filings/0001493152-24-045106.md) | [9.8](/filings/0001493152-26-013568.md) | [10.0](/filings/0001641172-25-023453.md) | [10.3](/filings/0001493152-25-021891.md) | [10.4](/filings/0001493152-25-021891.md) | [10.6](/filings/0001493152-26-037331.md) | [10.4](/filings/0001493152-26-037331.md) | [11.6](/filings/0001493152-26-037331.md) | [11.4](/filings/0001493152-25-021891.md) | [11.4](/filings/0001493152-26-037331.md) | [10.5](/filings/0001493152-26-037331.md) | [9.8](/filings/0001493152-26-037331.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,428 d](/filings/0001493152-24-045106.md) | [(344) d](/filings/0001641172-25-000274.md) | [612](/filings/0001641172-25-009938.md) | [1,177 d](/filings/0001641172-25-023453.md) | [1,934 d](/filings/0001493152-25-021891.md) | [136 d](/filings/0001493152-26-013568.md) | [(27.1)](/filings/0001493152-26-023045.md) | [140 d](/filings/0001493152-26-037331.md) | [1,351 d](/filings/0001493152-25-021891.md) | [(530) d](/filings/0001493152-26-013568.md) | [(228)](/filings/0001493152-26-023045.md) | [42.3 d](/filings/0001493152-26-037331.md) |
| Capital expenditure | $k | [1.3 d](/filings/0001493152-24-045106.md) | [27.2 d](/filings/0001641172-25-000274.md) | [18.3](/filings/0001641172-25-009938.md) | [182 d](/filings/0001641172-25-023453.md) | [192 d](/filings/0001493152-25-021891.md) | [46.2 d](/filings/0001493152-26-013568.md) | [121](/filings/0001493152-26-023045.md) | [142 d](/filings/0001493152-26-037331.md) | [71.1 d](/filings/0001493152-25-021891.md) | [20.6 d](/filings/0001493152-26-013568.md) | [25.0](/filings/0001493152-26-023045.md) | [50.7 d](/filings/0001493152-26-037331.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,695](/filings/0001493152-23-041026.md) | [4,392](/filings/0001493152-24-019215.md) | [4,074](/filings/0001493152-24-031586.md) | [4,388](/filings/0001493152-24-045106.md) | [4,114](/filings/0001641172-25-009938.md) | [4,722](/filings/0001641172-25-023453.md) | [4,231](/filings/0001493152-25-021891.md) | [4,262](/filings/0001493152-26-023045.md) | [4,252](/filings/0001493152-26-037331.md) | [4,387](/filings/0001493152-25-021891.md) | [4,393](/filings/0001493152-26-023045.md) | [4,461](/filings/0001493152-26-037331.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,494,994 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001493152-26-037331.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.